About ContraFect

Bringing first-in-class, first-in-field molecules into the clinic to disrupt the current anti-infective therapeutic landscape.

Overview

We are a biotechnology company focused on developing treatments for drug resistant, life-threatening infectious diseases. Our lysin and monoclonal antibody products represent new approaches to treating infections.

Technology

Molecular Treatments for Infectious Diseases

Product Candidates

Next generation anti-infectives

Program Research Candidate Section IND-Enabling Phase 1 Phase 2
Lysin Candidates
CF-301* – S. aureus - Complicated Bacteremia
Research Phase complete
Candidate Section Phase complete
IND-Enabling Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
CF-303 – S. pneumoniae
Research Phase in progress
Candidate Section Phase not started
IND-Enabling Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
CF-304 – S. faecalis and E. faecium
Research Phase in progress
Candidate Section Phase not started
IND-Enabling Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
CF-305 – S. agalactiae
Research Phase in progress
Candidate Section Phase not started
IND-Enabling Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
CF-306 – B. anthracis
Research Phase in progress
Candidate Section Phase not started
IND-Enabling Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
CF-307 – Group B Streptococcus
Research Phase in progress
Candidate Section Phase not started
IND-Enabling Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
Antibody Candidates
CF-404 – Seasonal and Pandemic Influenza
Research Phase complete
Candidate Section Phase complete
IND-Enabling Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
  • *CF-301 has been granted Fast Track Designation from the FDA for the treatment of Staph aureus bacteremia.

Corporate Strategy

Our strategy is to use our first-in-class therapies to achieve a leadership position in the treatment of life-threatening infectious diseases, including those caused by drug-resistant pathogens. We plan to achieve commercialization of therapeutic products through discovery, acquisition and development of protein and antibody products.

17

Currently holding 17 different families of Patents

Leadership

Our team boasts a track record of creating shareholder value.

Steven C. Gilman, Ph.D.

Steven C. Gilman, Ph.D.

Chairman and Chief Executive Officer

Dr. Gilman most recently served as the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals until its acquisition by Merck & Co. Prior to joining Cubist in 2008, Dr. Gi...

View Full Profile »
Cara Cassino, M.D.

Cara Cassino, M.D.

Chief Medical Officer

Dr. Cassino has over 20 years of experience as a clinician and executive in healthcare, including over 14 years of experience in pharmaceutical product development and over 20 successful regulatory submissions in the US and glo...

View Full Profile »
Michael Wittekind, Ph.D.

Michael Wittekind, Ph.D.

Chief Scientific Officer and Sr. Vice President, Research

Dr. Wittekind has more than 20 years of industry experience in biotechnology research and management. Prior to joining ContraFect, Dr. Wittekind served as the Executive Director of Research for Amgen Inc, where he directed the ...

View Full Profile »
Josh Muntner

Josh Muntner

Senior Vice President, Business Development

Mr. Muntner has more than 15 years of transaction experience assisting life sciences companies with financing and M&A advisory transactions. Prior to joining ContraFect, he served as Managing Director and Co-He...

View Full Profile »
Nancy Dong

Nancy Dong

VP, Controller

Ms. Dong has more than 20 years of experience in accounting, strategic planning, budgeting and forecasting, organizational development, financial systems and controls. She served as controller at XL Marketing and Alley Corp pri...

View Full Profile »
Michael Messinger, CPA

Michael Messinger, CPA

Vice President, Finance

Mr. Messinger has more than 15 years of experience in finance, accounting and forecasting for clinical development. He served as Controller of Coelacanth Corporation prior to his role as Director of Finance for Lexicon Pharmace...

View Full Profile »
Natalie Bogdanos

Natalie Bogdanos

General Counsel and Corporate Secretary

Ms. Bogdanos has more than 17 years of in-depth legal experience across many areas of law including contract, intellectual property, licensing, regulatory, corporate governance, securities and litigation. Prior to joining Contr...

View Full Profile »
Steven C. Gilman, Ph.D.

Steven C. Gilman, Ph.D.

Chairman and Chief Executive Officer

Dr. Gilman most recently served as the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals until its acquisition by Merck & Co. Prior to joining Cubist in 2008, Dr. Gi...

View Full Profile »
Sol Barer, Ph.D.

Sol Barer, Ph.D.

Lead Director

Dr. Barer joined Celanese Research Company in 1974 and formed the Biotechnology Group that was spun out to form Celgene. Dr. Barer was Chairman and Chief Executive Officer from May 1, 2006 until June 16, 2010 and served a...

View Full Profile »
Roger J. Pomerantz, M.D., F.A.C.P.

Roger J. Pomerantz, M.D., F.A.C.P.

Vice Chairman

Dr. Pomerantz was formerly Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc. where he oversaw all licensing and acquisitions at Merck Research Laboratories. Previously, he served as ...

View Full Profile »
Isaac Blech

Isaac Blech

Founder and private financier of biotechnology companies

Mr. Blech's current roles include Director of ContraFect Corporation, Founder and Vice Chairman of Cerecor, Inc., a company developing new treatments for central nervous systems disorders, Vice Chairman of Edge Therapeutics, In...

View Full Profile »
Cary W. Sucoff

Cary W. Sucoff

Owner, Equity Source Partners LLC, an advisory and consulting firm

Mr. Sucoff has more than 30 years of securities industry experience encompassing supervisory, banking and sales responsibilities. He has participated in the financing of more than 100 public and private companies, raising...

View Full Profile »
David N. Low, Jr.

David N. Low, Jr.

Director

Mr. Low has worked as an investment banker since 1987, with broad investment and advisory experience in the life sciences, biotechnology and medical technology sectors. Mr. Low currently serves as a Senior Advisor at Lazard Fre...

View Full Profile »
Michael J. Otto, Ph.D.

Michael J. Otto, Ph.D.

Director

Dr. Otto served as Chief Scientific Officer of Pharmasset from October 1999 until February 2012, when the company was acquired by Gilead Sciences. He led the research team responsible for the discovery of sofosbuvir for the tre...

View Full Profile »